Early aberrant gene expression in primary non-small cell carcinomas: a future diagnostic tool? | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article Text

Miscellaneous

Early aberrant gene expression in primary non-small cell carcinomas: a future diagnostic tool?

Free

S E A Fairbairn

Specialist Research Registrar, Department of Respiratory Medicine, Royal Gwent Hospital, South Wales, UK; docsara2001@yahoo.com

https://doi.org/10.1136/thx.2004.la0132

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

▴ Smith SL, Gugger M, Hoban P, et al. S100A2 is strongly expressed in airway basal cells, preneoplastic and primary non-small cell lung carcinomas. Br J Cancer2004;91:1515–24

The S100A2 gene has previously been shown by this group to be significantly increased in non-small cell lung cancer. This study examined the expression of S100A2 in primary non-small cell lung carcinomas (NSCLC) with matched normal bronchial epithelium. Tumour tissue was obtained from 48 patients (37 men, 11 women) with resectable NSCLC (20 …